MAY 26, 2020 7:30 AM PDT

The Hunt for Rare Immune Cells, to InfinityFlow and Beyond

WRITTEN BY: Tara Fernandez

 

The immune landscape is staggeringly complex, with a myriad of genetically and functionally distinct immune cell subpopulations. Researchers have developed a new tool called InfinityFlow to help them classify the identities of these cell subsets with greater precision using artificial intelligence.

White blood cells account for just 1 percent of all blood cells, but form a critical frontline against viruses, bacteria, parasites and other foreign invaders. Produced in the bone marrow, this heterogeneous mix of cell subtypes include monocytes, neutrophils, basophils, and eosinophils — each with their own highly specialized biology and role. 

Immunophenotyping, the protocol used for identifying whilte blood cells, uses a standard “cluster of differentiation” (CD) nomenclature based on the presence of specific cell surface markers. For instance, T-lymphocytes are also known as CD4 cells, and can be distinguished from other white blood cells based on the expression of a CD4 receptor on their cell surface. With research advances, this CD marker library is expanding and immunologists are challenged with accurately assigning markers to immune cell subtypes that may bear only subtle differences in function and anatomical location.

Florent Ginhoux and his team from the Singapore Immunology Network (SIgN) have published a study in Immunology, describing a new method driven by artificial intelligence that characterizes immune cells with unprecedented accuracy based on a panel of 332 markers.

InfinityFlow has revealed the presence of rare immune cell subsets with important implications in autoimmune disease. The CD14 marker was previously thought to be unique to monocytes. However, InfinityFlow analysis has revealed that a tiny fraction of CD14-positive cells are not monocytes at all, but instead dendritic cells, tree-shaped cells known to promote inflammation.

These newly defined dendritic cells were found to contribute to the onset and progression of systemic lupus erythematosus, an autoimmune disease exacerbated by the pro-inflammatory molecules that dendritic cells secrete. InfinityFlow could potentially revolutionize research and drug development for diseases such as cancer, by more precisely profiling immune cells.

“From a clinical perspective, we may get to a point where we can pinpoint which immune cell is the ‘bad guy’ and develop drugs to kill or remove it,” said Ginhoux.

 

 

Sources: A*Star Research, Immunity.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 14, 2020
Immunology
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
MAY 14, 2020
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
Antibodies are a powerful countermeasure against COVID-19. Not only can they relieve symptoms in patients experiencing s ...
JUN 10, 2020
Immunology
Natural Killer Cells with "Memory" to Target Hepatitis B
JUN 10, 2020
Natural Killer Cells with "Memory" to Target Hepatitis B
An immune cell type thought to be restricted to the general, first response to pathogenic invaders may actually have som ...
AUG 11, 2020
Drug Discovery & Development
Scientists Discover Key Gene Behind Antibiotic Resistance
AUG 11, 2020
Scientists Discover Key Gene Behind Antibiotic Resistance
Scientists from Oxford University have shown that a single gene can make some strains of Staphylococcus aureus (the bact ...
AUG 25, 2020
Immunology
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
AUG 25, 2020
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
In a new study published in Cell, researchers have identified a metabolic enzyme that could have powerful tumor-killing ...
AUG 24, 2020
Drug Discovery & Development
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
AUG 24, 2020
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help th ...
SEP 07, 2020
Immunology
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
SEP 07, 2020
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
The ability to edit the human genome using CRISPR has been heralded as a revolution in medicine. However, one of the big ...
Loading Comments...